GALT vs SPG · $142.4M cap vs rev $3.55B
Galectin Therapeutics Inc (GALT) versus SPG (SPG) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
SPG (SPG) common stock.
GALT does not have a complete income-statement cache yet.
Latest reported SPG revenue for 2026-06-30 was $3.55B. Net income was $1.14B. SPG currently screens at market cap $0.
GALT currently screens at market cap $142.4M. SPG currently screens at market cap $0.
Not investment advice. Open the GALT and SPG stock pages for the full models.
Not investment advice.